clinical trial · NCT07499544
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
Huahui Health·phase3·recruiting·n = 160
Chronic Hepatitis D InfectionLibevitug 20 mg/kgLibevitug 10 mg/kgDelayed treatment with libevitug
brief summary
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
started
Apr 22, 2026
primary completion
Sep 12, 2028
completion
Jan 29, 2030
last updated
Jun 10, 2026
official title
A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol